AEterna Zentaris (AEZS) has achieved European approval for their adult growth hormone deficiency "GHD" drug Macrilen (macimorelin). Investors expected a subsequent partner announcement to market Macrilen throughout Europe. However, a recent press release announced that the board of directors had made a "special committee" of independent members to review strategic options for the company. This story gets even more interesting due to the company bringing in Torreya, a global investment bank known for facilitating large M&A deals in the biotech sector.
On March 26th, the company reported their Q4/2018 earnings report with